DGAP-Adhoc: MOLOGEN AG: Sale of the essential assets
|
DGAP-Ad-hoc: MOLOGEN AG / Key word(s): Insolvency Mologen AG - Sale of the essential assets The insolvency administrator of Mologen AG (WKN A2LQ90) has accepted the offer to sell a substantial part of Mologen's assets (in particular delvopments associated with Lefitolimod and Enandim) to Gilead Sciences Inc. The purchase price will probably enable a dividend for creditors in the insolvency but will not be sufficient to satisfy all insolvency claims in full.
Please note: Claims arising from the convertible bonds 2016/2024 and 2017/2025 can only be filed through the joint representative of the bondholders, Dr. Marc Liebscher, c/o Dr. Späth & Partner Rechtsanwälte, Kurfürstendamm 102, 10711 Berlin."
08-May-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | MOLOGEN AG |
| Königin-Luise-Str. 27 | |
| 14195 Berlin | |
| Germany | |
| Phone: | 030 / 841788-0 |
| Fax: | 030 / 841788-50 |
| E-mail: | [email protected] |
| Internet: | www.mologen.com |
| ISIN: | DE000A2LQ900 |
| WKN: | A2LQ90 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1039707 |
| End of Announcement | DGAP News Service |
|
|
1039707 08-May-2020 CET/CEST
